ArticleAmerican journal of translational research2026
Combined therapy with vitamin D, mesalazine, and microecological preparations improves clinical outcome in ulcerative colitis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of adjunctive vitamin D to mesalazine combined with microecological preparations in the treatment of ulcerative colitis.
methodsA retrospective analysis was conducted on the clinical data of 103 patients with ulcerative colitis. The conventional treatment group (n=54) received mesalazine plus microecological preparations, while the combined treatment group (n=49) received additional vitamin D. Both groups were treated for one month. The efficacy, safety, and mechanistic indicators were compared between the two groups.
resultsAfter one month of treatment, the combined treatment group showed better results than the conventional treatment group in terms of endoscopic findings, disease activity, inflammatory indicators, intestinal barrier function, oxidative stress levels, and the Inflammatory Bowel Disease Questionnaire (all P<0.05). No significant difference was found in the incidence of adverse reactions (P>0.05).
conclusionVitamin D supplementation on the basis of mesalazine combined with microecological preparations can improve the clinical efficacy, mucosal healing, and related biological indicators in patients with ulcerative colitis, and has good safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.